Overview

MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine maximum tumor shrinkage, time to progression, survival, drug concentration, and degree of skin toxicity.
Phase:
Phase 3
Details
Lead Sponsor:
University of Chicago
Collaborator:
Bayer
Treatments:
Niacinamide
Sorafenib